<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683772</url>
  </required_header>
  <id_info>
    <org_study_id>MA-15-12-15</org_study_id>
    <nct_id>NCT02683772</nct_id>
  </id_info>
  <brief_title>Astral VAPS AutoEPAP Clinical Trial</brief_title>
  <official_title>The Evaluation of the Astral VAPS AutoEPAP Treatment Algorithm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ResMed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic respiratory failure such as those associated with Chronic Obstructive
      Pulmonary Disease (COPD), Obesity Hypoventilation Syndrome (OHS), Obstructive Sleep Apnea
      (OSA) or Neuromuscular Disease (NMD) are increasingly managed with domiciliary non-invasive
      positive pressure ventilation (NIPPV). The aim of this study is to now compare the Automatic
      Expiratory Positive Airway Pressure (AutoEPAP) algorithm with a fixed manual EPAP in iVAPS
      mode on an Astral mixed mode ventilator. It is proposed that the automatic settings of
      AutoEPAP will be as effective at managing respiratory failure and upper airway obstruction
      (UAO) as manual EPAP on the Astral device. Specifically demonstrating that the AutoEPAP
      function is as effective at treating UAO as manual EPAP.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2016</start_date>
  <completion_date type="Actual">July 6, 2017</completion_date>
  <primary_completion_date type="Actual">March 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patients were masked to the mode of treatment. The Core Lab was masked to the mode of treatment for all patients.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ODI4%</measure>
    <time_frame>1 night comparison</time_frame>
    <description>Comparison of Oxygen Desaturation Index 4% (ODI4%) values between groups by using mean ODI4% (#events/hour)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep efficacy</measure>
    <time_frame>1 night comparison</time_frame>
    <description>To assess sleep efficacy between groups by using rapid eye movement sleep (REM) (% of total sleep time) and sleep staging time (% of total sleep time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arousal Index (AI)</measure>
    <time_frame>1 night comparison</time_frame>
    <description>To assess sleep parameters between groups using mean AI (#events/hour)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apnea Hypopnea Index (AHI)</measure>
    <time_frame>1 night comparison</time_frame>
    <description>To assess sleep-breathing parameters between groups using mean AHI (#events/hour)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nadir arterial oxygen saturation (SpO2)</measure>
    <time_frame>1 night comparison</time_frame>
    <description>To assess Sleep-breathing parameters between groups using mean SpO2 (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>transcutaneous carbon dioxide (TcCO2)</measure>
    <time_frame>1 night comparison</time_frame>
    <description>To assess Sleep-breathing parameters between groups using mean TcCO2 (mmHg)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Upper Airway Obstruction</condition>
  <condition>Respiratory Insufficiency</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Astral device will be set using iVAPS with manual EPAP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Astral device will be set using iVAPS with AutoEPAP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Astral</intervention_name>
    <description>Astral ventilator</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for the study are:

          1. Participant has ability to provide written informed consent

          2. Participants aged ≥18 years old

          3. Participant has documented respiratory failure (e.g. sleep hypoventilation with
             historical PtCO2 increase ≥ 10mmHg) and/or daytime hypercapnia (&gt;45 mmHg)

          4. Participant is currently using non-invasive positive pressure ventilation in ST or
             VAPS mode for ≥ 3 months

          5. Participants with a previously documented AHI ≥ 5/hr

          6. Participants with a recently (≤ 12 months ago) reviewed EPAP setting

        Exclusion criteria for the study are:

          1. Participants are not compliant on NIPPV (e.g. &lt; 4 hr/night)

          2. Participants who are pregnant

          3. Participants on oxygen therapy ≥5 L/min

          4. Participants with an invasive interface (e.g. tracheostomy)

          5. Participants who have had an acute exacerbation within the last 3 months that resulted
             in a hospitalisation

          6. Participants who are acutely ill, medically complicated or who are medically unstable

          7. Participants in whom NIPPV therapy is otherwise medically contraindicated

          8. Participants who have had surgery of the upper airway, nose, sinus, or middle ear
             within the previous 90 days

          9. Participants with untreated, non-OSA sleep disorders, including but not limited to;
             insomnia, periodic limb movement syndrome, or restless legs syndrome.

         10. Participants who have the following pre-existing conditions: severe bullous lung
             disease, recurrent pneumothorax or pneumomediastinum, cerebrospinal fluid leak, recent
             cranial surgery or trauma.

         11. Participant does not comprehend English

         12. Participant is unable or unwilling to provide written informed consent

         13. Participant is physically and/or mentally unable to comply with the protocol

         14. Participant is not suitable to participate in the trial for any other reason in the
             opinion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Wolfe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lisa F. Wolfe, MD</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Budweiser S, Jörres RA, Riedl T, Heinemann F, Hitzl AP, Windisch W, Pfeifer M. Predictors of survival in COPD patients with chronic hypercapnic respiratory failure receiving noninvasive home ventilation. Chest. 2007 Jun;131(6):1650-8.</citation>
    <PMID>17565016</PMID>
  </reference>
  <reference>
    <citation>Masa JF, Celli BR, Riesco JA, Hernández M, Sánchez De Cos J, Disdier C. The obesity hypoventilation syndrome can be treated with noninvasive mechanical ventilation. Chest. 2001 Apr;119(4):1102-7.</citation>
    <PMID>11296176</PMID>
  </reference>
  <reference>
    <citation>Remmers JE, deGroot WJ, Sauerland EK, Anch AM. Pathogenesis of upper airway occlusion during sleep. J Appl Physiol Respir Environ Exerc Physiol. 1978 Jun;44(6):931-8.</citation>
    <PMID>670014</PMID>
  </reference>
  <reference>
    <citation>Ward S, Chatwin M, Heather S, Simonds AK. Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. Thorax. 2005 Dec;60(12):1019-24.</citation>
    <PMID>16299118</PMID>
  </reference>
  <reference>
    <citation>Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med. 2003 Jul 1;168(1):10-48. Review.</citation>
    <PMID>12826594</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <disposition_first_submitted>March 7, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 7, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 9, 2018</disposition_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NIV, NIPPV, ventilation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
    <mesh_term>Airway Obstruction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>March 21, 2018</submitted>
    <returned>April 19, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

